Impact of Preexisting and Induced Humoral and Cellular Immune Responses in an Adenovirus-Based Gene Therapy Phase I Clinical Trial for Localized Mesothelioma
- 20 September 1998
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 9 (14) , 2121-2133
- https://doi.org/10.1089/hum.1998.9.14-2121
Abstract
Little is known about the immune responses induced by recombinant adenoviral (Ad) vectors in humans. The humoral and cellular immune responses were therefore analyzed in 21 patients with localized malignancy (mesothelioma), who received intrapleurally high doses of a replication-defective Ad5 vector carrying a suicide gene. Eight of 21 patients had pretreatment titers of neutralizing antibodies (NAb) to Ad at ≥1:100. Peripheral blood mononuclear cells (PBMCs) proliferated in response to adenoviral 5 structural proteins before treatment in 17 of 21 patients. Preexisting humoral and cellular immunity did not preclude gene transfer. Vector instillation induced high titers of nonneutralizing and neutralizing anti-Ad antibody (4- to 341-fold increase in 18 of 20 patients) in a dose-dependent manner. Three patients generated antibodies to the transgene, herpes simplex virus thymidine kinase. Ad5-specific proliferation of PBMCs increased significantly (>3-fold) after vector administration in 12 of 21 patients in a dose-dependent manner. Thus, replication-defective Ad5 administered intrapleurally induced significant humoral and cellular immune responses that induced no obvious adverse clinical sequelae. The humoral and cellular immune responses were analyzed in 21 patients with localized malignancy (mesothelioma), who received intrapleurally high doses of a replication-defective Ad5 vector carrying a suicide gene. Eight of 21 patients had pretreatment titers of neutralizing antibodies (NAb) to Ad at ≥1:100. Peripheral blood mononuclear cells (PBMCs) proliferated in response to adenoviral 5 structural proteins before treatment in most patients. Preexisting immunity to Ad did not preclude gene transfer. Vector instillation induced high titers of nonneutralizing and NAb production in most patients; three patients generated antibodies to HSV tk transgene. Ad5-specific proliferation of PBMCs increased significantly (>3-fold) after vector administration in 12 of 21 patients in a dose-dependent manner. Thus, replication-defective Ad5 administered intrapleurally induces significant humoral and cellular immune responses that induced no obvious adverse clinical sequelae.Keywords
This publication has 39 references indexed in Scilit:
- Cytotoxic T Lymphocyte Responses to Proteins Encoded by Heterologous Transgenes TransferredIn Vivoby Adenoviral VectorsHuman Gene Therapy, 1997
- Alveolar Macrophages Inhibit Retrovirus-Mediated Gene Transfer to Airway EpitheliaHuman Gene Therapy, 1997
- The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctionsGene Therapy, 1997
- Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expressionGene Therapy, 1997
- Safety of Intrapleurally Administered Recombinant Adenovirus Carrying Herpes Simplex Thymidine Kinase DNA Followed by Ganciclovir Therapy in Nonhuman PrimatesHuman Gene Therapy, 1996
- Treatment of Advanced Mesothelioma with the Recombinant Adenovirus H5.010RSVTK: A Phase 1 Trial (BB-IND 6274)Human Gene Therapy, 1996
- Virus‐specific, antibody‐secreting cells during upper respiratory infectionsJournal of Medical Virology, 1995
- The Role of Immunosuppression in the Efficacy of Cancer Gene Therapy Using Adenovirus Transfer of the Herpes Simplex Thymidine Kinase GeneAnnals of Surgery, 1995
- Antigen-presenting function of human peritoneum mesothelial cellsClinical and Experimental Immunology, 1995
- Quantitation of intrathecal measles virus IgG antibody synthesis rate: Subacute sclerosing panencephalitis and multiple sclerosisJournal of Neuroimmunology, 1994